Helicobacter pylori News and Research

RSS

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Study analyzes the resistance of H. pylori bacterium to antibiotics

A UPV/EHU study analyses the resistance of the Helicobacter pylori (H. pylori) bacterium to the antibiotics routinely used to treat the infection caused by this bacterium.

29 Nov 2021

New imaging technology for detecting MALT lymphomas could save patients numerous gastroscopies

A new imaging technique for the detection of MALT lymphomas, malignant tumours of the lymphatic system, could probably save patients numerous gastroscopies. A study group of MedUni Wien achieved a high imaging accuracy by way of PET/MR and by using a PET Tracer directed against a certain cell receptor. The results are currently published in the top journal "Blood" of the American Society of Hematology.

24 Sep 2021

Researchers identify eight primary factors that increase GI bleeding risk after heart attack

Researchers at Karolinska Institutet in Sweden have identified eight primary factors that increase the risk of a common bleeding complication after heart attack. Some of these factors are already known, but using machine learning techniques, the researchers have found additional predictors, such as smoking, blood pressure and blood glucose.

23 Aug 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Irritable bowel syndrome is linked to bacterial biofilms in the gut

One in six women and one in twelve men in Austria suffers from some form of IBS - therefore around one million people in all. Using currently available techniques, it is only possible to diagnose IBS by a process of elimination.

21 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Host protein mimicry of SARS-CoV-2 receptor binding motif

In a new study, structural bioinformatics approaches are employed to investigate the potential mimicry of the receptor-binding motif (RBM) of these three coronaviruses, finding that several proteins from both human and non-human sources were similar to each, with implications regarding the mechanism of infection and tropism of SARS-CoV-2.

29 Apr 2021

Cholestenone could be a new antibacterial drug against H. pylori

Helicobacter pylori (H. pylori), a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and malignant lymphoma of the stomach.

27 Apr 2021

Study finds a bacterial molecule that may be key to fighting gastric cancer

Humans are exposed to many types of bacteria daily, the majority of which are harmless. However, some bacteria are pathogenic, which means they can cause disease.

12 Apr 2021

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

Scientists worldwide are conducting extensive research to understand the nature of the virus, its transmission kinetics, etc. They have found a strong correlation between the ABO blood group and SARS-CoV-2 regarding its morbidity and mortality.

9 Apr 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

A new method to determine how carcinogenic bacteria reach their targets

The gram-negative bacteria Helicobacter pylori (H. pylori) colonize the stomachs of the majority of the world's population.

11 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

A new animal study, published in the Journal of Clinical Biochemistry and Nutrition, suggests regular walnut consumption may be a promising intervention for reducing negative outcomes associated with Helicobacter pylori (H. pylori) infection, a widespread bacterial infection that affects more than half of the world's population.